Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01744912 · ClinicalTrials.gov registry record · Phase 1
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
A Phase 1 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01744912 is a Phase 1 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT01744912, a Phase 1 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ublituximab in combination with lenalidomide (Revlimid®) is safe and effective in patients with B-Cell Lymphoid Malignancies who have relapsed or are refractory after CD20 directed antibody therapy.
Interventions
- DRUG Lenalidomide
- DRUG Ublituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-11-21 |
| Est. Completion | 2014-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01744912
The ClinicalTrials.gov registry entry for NCT01744912 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT01744912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01744912 about?
NCT01744912 is a clinical study titled "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies". The purpose of this study is to determine whether ublituximab in combination with lenalidomide (Revlimid®) is safe and effective in patients with B-Cell Lymphoid Malignancies who have relapsed or are refractory after CD20 directed antibody therapy.
What is the current status of trial NCT01744912?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2012-11-21. Estimated completion is 2014-02-07.
What interventions are being tested in trial NCT01744912?
The interventions under investigation include: Lenalidomide (DRUG), Ublituximab (DRUG).
Who is sponsoring clinical trial NCT01744912?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.